
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc. is experiencing significant growth across multiple segments, with management reporting that the Integrity product line is expected to achieve over 100% revenue growth in 2025 compared to 2024. The company has also demonstrated resilience in its international markets, as overseas osteoarthritis pain revenue rose by 13% in the first quarter, complemented by a robust 21% increase in international OA pain revenue from the previous year. Additionally, the regenerative solutions business reported an impressive 41% growth in the quarter, driven primarily by strong demand for the Integrity patch.
Bears say
Anika Therapeutics Inc experienced a decline in revenue, reporting $27.8 million, which reflects a 5.9% decrease compared to the prior year, amidst challenges such as production yield issues. The company also faced a disappointing gross margin of 56%, falling short of the estimated 58%, which adds to concerns about operational efficiency. Additionally, international revenue from osteoarthritis pain management decreased by 10%, indicating persistent difficulties in their product demand and sales performance.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares